Fegade Bharti S, Jadhav Shailaja B, Chaudhari Somdatta Y, T Tandale Deepak, Shantaram Uttekar Pravin, Tabrez Shams, Khan Mohd Shahnawaz, Zaidi Syed Kashif, Mukerjee Nobendu, Ghosh Arabinda
Department of Pharmaceutical Chemistry, Modern College of Pharmacy, Nigdi, Pune, Maharashtra, India.
Department of Pharmaceutical Chemistry, Gahlot Institute of Pharmacy, Koparkhairane, Navi Mumbai, Maharashtra, India.
J Biomol Struct Dyn. 2024;42(24):13793-13802. doi: 10.1080/07391102.2023.2278746. Epub 2023 Nov 25.
Hormone-related breast cancer is mostly caused by interactions with estrogen receptor alpha (ER-α), which functions as a transcription factor to control the transcription of numerous genes. Flavones are considered a good substrate for the estrogen receptor. Substitution of the N-heterocyclic ring on the flavon structure may potentiate its anticancer effect. A series of flavon derivatives with an N-heteroaryl ring at the 4' position of the B ring of flavon were designed, prepared and evaluated for breast cancer activity. Binding interactions of the PzFL, PzF, PiFL, PiF and IFL compounds with ER-α were studied by molecular docking. Molecular dynamics simulation studies were carried out in order to determine the stability and convergence of protein-ligand complexes. The compounds were produced by cyclizing chalcones and chalcones were produced by Claisen-Schmidt condensation of substituted aldehydes and 2-hydroxy acetophenone. Breast cancer activity was evaluated by the MTT assay on MCF-7 cell lines. Also, compounds were studied for their estrogen receptor binding potential on the same cell lines. Molecular docking of compounds showed a good docking score. The molecular dynamics of these compounds expressed stable root mean square deviation, stable radius of gyration and low binding energy, suggesting that ligand bound to protein is quite stable in the complex. MTT assay on MCF-7 cell lines reported PzF and IFL were the most active compounds with lower IC values. ER-α binding assay of these compounds revealed the presence of binding interactions with receptors. This study offers a viable reference point for the design of flavon-incorporated N-heterocyclic ring derivatives as breast cancer compounds.Communicated by Ramaswamy H. Sarma.
激素相关的乳腺癌主要由与雌激素受体α(ER-α)的相互作用引起,ER-α作为一种转录因子,控制众多基因的转录。黄酮类化合物被认为是雌激素受体的良好底物。黄酮结构上N-杂环的取代可能会增强其抗癌效果。设计、制备并评估了一系列在黄酮B环4'位带有N-杂芳基环的黄酮衍生物的乳腺癌活性。通过分子对接研究了PzFL、PzF、PiFL、PiF和IFL化合物与ER-α的结合相互作用。进行分子动力学模拟研究以确定蛋白质-配体复合物的稳定性和收敛性。这些化合物通过查耳酮环化制备,而查耳酮则通过取代醛与2-羟基苯乙酮的克莱森-施密特缩合反应制备。通过MTT法在MCF-7细胞系上评估乳腺癌活性。此外,还在相同细胞系上研究了这些化合物的雌激素受体结合潜力。化合物的分子对接显示出良好的对接分数。这些化合物的分子动力学表现出稳定的均方根偏差、稳定的回转半径和低结合能,表明配体与蛋白质在复合物中结合相当稳定。在MCF-7细胞系上的MTT分析报告称,PzF和IFL是活性最高的化合物,IC值较低。这些化合物的ER-α结合分析揭示了与受体存在结合相互作用。本研究为设计含黄酮的N-杂环衍生物作为乳腺癌化合物提供了一个可行的参考点。由拉马斯瓦米·H·萨尔马传达。